Personal CFO Solutions’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $240K | Sell |
11,149
-1,003
| -8% | -$21.6K | 0.04% | 404 |
|
|
2025
Q1 | $202K | Sell |
12,152
-78
| -0.6% | -$1.3K | 0.04% | 428 |
|
|
2024
Q4 | $224K | Buy |
+12,230
| New | +$224K | 0.04% | 412 |
|
|
2024
Q3 | – | Sell |
-12,614
| Closed | -$205K | – | 562 |
|
|
2024
Q2 | $205K | Sell |
12,614
-177
| -1% | -$2.88K | 0.03% | 506 |
|
|
2024
Q1 | $237K | Sell |
12,791
-37
| -0.3% | -$684 | 0.04% | 472 |
|
|
2023
Q4 | $402K | Buy |
12,828
+20
| +0.2% | +$626 | 0.07% | 288 |
|
|
2023
Q3 | $267K | Buy |
12,808
+27
| +0.2% | +$563 | 0.05% | 351 |
|
|
2023
Q2 | $306K | Sell |
12,781
-79
| -0.6% | -$1.89K | 0.06% | 324 |
|
|
2023
Q1 | $242K | Buy |
12,860
+14
| +0.1% | +$263 | 0.05% | 380 |
|
|
2022
Q4 | $205K | Sell |
12,846
-3,500
| -21% | -$55.7K | 0.04% | 419 |
|
|
2022
Q3 | $267K | Hold |
16,346
| – | – | 0.07% | 277 |
|
|
2022
Q2 | $230K | Buy |
16,346
+500
| +3% | +$7.04K | 0.05% | 345 |
|
|
2022
Q1 | $384K | Buy |
15,846
+1,000
| +7% | +$24.2K | 0.08% | 248 |
|
|
2021
Q4 | $347K | Sell |
14,846
-13,154
| -47% | -$307K | 0.07% | 280 |
|
|
2021
Q3 | $465K | Buy |
28,000
+2,800
| +11% | +$46.5K | 0.1% | 200 |
|
|
2021
Q2 | $615K | Hold |
25,200
| – | – | 0.13% | 159 |
|
|
2021
Q1 | $650K | Buy |
25,200
+3,400
| +16% | +$87.7K | 0.14% | 133 |
|
|
2020
Q4 | $1.17M | Hold |
21,800
| – | – | 0.29% | 78 |
|
|
2020
Q3 | $1K | Buy |
21,800
+1,000
| +5% | +$46 | 0.33% | 51 |
|
|
2020
Q2 | $1.01M | Buy |
20,800
+3,100
| +18% | +$150K | 0.3% | 76 |
|
|
2020
Q1 | $748K | Buy |
17,700
+8,100
| +84% | +$342K | 0.27% | 83 |
|
|
2019
Q4 | $411K | Buy |
+9,600
| New | +$411K | 0.12% | 166 |
|